Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells

Trastuzumab (Herceptin(®)), a humanized IgG1 antibody raised against the human epidermal growth factor receptor 2 (HER2/neu), is the main antibody in clinical use against breast cancer. Pre-clinical evidence and clinical studies indicate that trastuzumab employs several anti-tumour mechanisms that m...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Karagiannis, Panagiotis, Singer, Josef, Hunt, James, Gan, Samuel K. E., Rudman, Sarah M., Mechtcheriakova, Diana, Knittelfelder, Regina, Daniels, Tracy R., Hobson, Philip S., Beavil, Andrew J., Spicer, James, Nestle, Frank O., Penichet, Manuel L., Gould, Hannah J., Jensen-Jarolim, Erika, Karagiannis, Sophia N.
Format: Artigo
Langue:Inglês
Publié: 2008
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3017872/
https://ncbi.nlm.nih.gov/pubmed/18941743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-008-0607-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires